» Yes… sounds to good to be truth… for this reason: where are info about
» the trials? No dates? Images? NOTHING.
Dr. Jerry Shapiro to Chair TrichoScience Medical Advisory Board
October 19, 2009 – Vancouver BC.
TrichoScience Innovations Inc. (TrichoScience) has announced the formation of a new Medical Advisory Board under the Chairmanship of Dr. Jerry Shapiro (MD, FRCPC), TrichoScience’s Medical Director for North America.
The Medical Advisory Board will be made up of recognized medical and scientific professionals with backgrounds in hair disorders and restoration, alopecia and hair follicle endocrinology and morphogenesis. The Advisory Board will offer on-going advice and counsel pertaining to the development of TrichoScience’s hair cell replication technology and procedure.
In announcing the formation of the Medical Advisory Board, Dr. Shapiro said, “It is important that TrichoScience establishes on-going access to the thinking and experience of individuals who are actively involved in the most current medical practices and scientific technologies involving hair. Our Medical Advisory Board members, who will be announced over the coming months, will bring this experience to TrichoScience. They will also be professionals who are recognized for their work in this important field.”
Dr. Shapiro, a specialist in hair disorders for the past 22 years, holds dual academic appointments as Clinical Professor and Adjunct Professor at both the University of British Columbia and New York University Schools of Medicine. He is a past President of both the North American Hair Research Society and the Canadian Society of Investigative Dermatology and President of the Canadian Hair Research Foundation.
Dr. Shapiro has served as Chairman of the World Congress of Hair Research Societies, lectured internationally and trained dermatologists from North America, Europe, Asia and South America in the field of hair biology and hair transplantation. He began the first comprehensive basic science, medical and surgical hair training fellowship in the world and is considered one of the most experienced hair dermatologists internationally. He also runs one of the busiest hair clinics in the world.
TrichoScience Completes Initial Phase of Private Placement Funding
Sept 3, 2009 – Vancouver BC.
TrichoScience Innovations Inc. (TrichoScience) has announced the completion of the first phase of its initial round of private financing. This funding allows the Company to immediately commence human clinical trials which will begin in Europe in September, 2009.
The European human clinical trials are being directed by TrichoScience Vice Chairman & Chief Medical Director for Europe, Dr. Rolf Hoffmann who, in partnership with Dr. Kevin McElwee, the Company’s Chief Scientific Officer, has been responsible for research and development of the unique TrichoScience hair cell replication procedure.
In announcing completion of the initial round of financing, TrichoScience President & CEO, Matt Wayrynen said, “This is a very important step for TrichoScience. Over the past seven years a lot of effort, time and money have gone into the development of the unique TrichoScience procedure by a truly dedicated team of medical and scientific professionals. The procedure has been proven safe and effective in pre-clinical research and testing, and we are now able to carry this success forward into the human clinical trials phase.”
TrichoScience will regularly issue up-dated information throughout the clinical human trials phase.
TrichoScience Innovations Inc. (TrichoScience) is a privately-held life sciences company based in Vancouver, Canada. The company is developing a new hair cell replication technique that has the potential to become the world’s first non-surgical, permanent cure for pattern baldness and general hair loss in both men and women. The procedure, a non-surgical, cellular implantation method that replicates a patient’s hair cells from their own healthy hair follicles, is being developed by a team of recognized research scientists and medical experts in the fields of hair growth, hair biology and dermatology. Patents covering the procedure have been issued in a number of international jurisdictions and are patent-pending in other major countries worldwide.
The TrichoScience procedure is not yet commercially available and is subject to human clinical trials followed by regulatory submission, review and approvals in Canada, Europe and the U.S. The TrichoScience procedure has been proven safe and effective in pre-clinical research and testing.